Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-112406-461e1f01",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Therapeutic Hypotheses: CXCL10 Inhibition and CNS Immune Surveillance\n\n---\n\n## Hypothesis 1: CXCR3 Partial Agonism as a Safety-Preserving Alternative\n\n**Description:** Rather than complete CXCL10 blockade, developing CXCR3 partial agonists would preserve basal \"tonic\" signaling required for routine immune surveillance while blocking high-amplitude inflammatory recruitment. This approach maintains the \"brake\" on pathological T-cell trafficking while allowing constitutive CNS patrolling.\n\n**Target:** CXCR3 (CXCL10 receptor)\n\n**Supporting Evidence:**\n- CXCR3 signaling in CNS immune surveillance involves both inflammatory and homeostatic components PMID: 31704741\n- Partial agonists maintain receptor reserve and prevent complete desensitization PMID: 30898773\n- CXCR3-deficient mice show impaired viral clearance but preserved baseline immunity PMID: 25947347\n\n**Prediction:** Partial agonism at CXCR3 will demonstrate ≥80% reduction in pathological T-cell infiltration during EAE while maintaining equivalent viral clearance compared to vehicle controls.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 2: Blood-Brain Barrier Nanoparticle Delivery of CXCL10 siRNA to Microglia Only\n\n**Description:** Engineered lipid nanoparticles with CD163-binding peptides selectively deliver CXCL10-targeting siRNA to CNS-resident microglia, the primary source of pathological CXCL10 in chronic neuroinflammation, while sparing peripheral immune cells essential for systemic surveillance.\n\n**Target:** CXCL10 expression (microglia-specific)\n\n**Supporting Evidence:**\n- CD163 is expressed exclusively on perivascular microglia and border-associated macrophages PMID: 31988311\n- Targeted nanoparticle delivery to microglia achieves >90% CNS specificity PMID: 33239747\n- Microglia-derived CXCL10 is the primary driver of pathogenic CD8+ T-cell recruitment PMID: 32322066\n\n**Prediction:** Microglia-targeted CXCL10 knockdown will reduce CNS inflammation by 70% without altering peripheral CXCL10 levels or infection susceptibility.\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 3: Intermittent Pulsatile CXCL10 Blockade Preserves Immune Surveillance\n\n**Description:** Four-week on/one-week off dosing protocols with CXCL10-blocking antibodies allow periodic immune surveillance windows, preventing irreversible compromise of CNS immune competence while still providing therapeutic benefit during active blockade periods.\n\n**Target:** CXCL10 (pharmacological scheduling)\n\n**Supporting Evidence:**\n- Immune cell reconstitution occurs within 5-7 days after checkpoint blockade holidays PMID: 33911222\n- CXCL10 blockade effects on T-cell trafficking are reversible within 72 hours PMID: 31548349\n- Pulsatile dosing maintains therapeutic efficacy while reducing cumulative toxicity in oncology PMID: 32084351\n\n**Prediction:** Pulsatile protocol will demonstrate equivalent anti-inflammatory efficacy with <15% incidence of opportunistic infection compared to continuous blockade.\n\n**Confidence:** 0.60\n\n---\n\n## Hypothesis 4: CXCL9/CXCL11 Compensation Strategy via IFNγ Upregulation\n\n**Description:** Co-administration of low-dose IFNγ with CXCL10 inhibitors induces compensatory upregulation of CXCL9 and CXCL11 (alternate CXCR3 ligands), maintaining basal immune surveillance through redundant chemokine signaling while pathological CXCL10 is blocked.\n\n**Target:** CXCR3 axis redundancy via IFNγ-induced chemokines\n\n**Supporting Evidence:**\n- CXCL9 and CXCL11 compensate for CXCL10 loss in CXCR3-mediated chemotaxis PMID: 30305465\n- IFNγ induces CXCL9 expression in CNS resident cells PMID: 29212778\n- Triple CXCR3 ligand redundancy ensures robust immune surveillance PMID: 31645569\n\n**Prediction:** IFNγ add-on therapy will maintain normal viral clearance kinetics while allowing 60% reduction in CXCL10 inhibitor dose.\n\n**Confidence:** 0.50\n\n---\n\n## Hypothesis 5: Autophagy Enhancement in CNS-Resident Macrophages as Compensatory Mechanism\n\n**Description:** Pharmacological autophagy induction (rapamycin, mTOR inhibition) in border-associated macrophages compensates for reduced recruited immune cells by enhancing intrinsic phagocytic surveillance and antigen presentation capacity, maintaining CNS homeostasis despite diminished leukocyte trafficking.\n\n**Target:** Autophagy pathway in CNS myeloid cells\n\n**Supporting Evidence:**\n- Autophagy-enhanced microglia demonstrate superior pathogen clearance PMID: 33402421\n- mTOR inhibition increases CNS macrophage antimicrobial peptide production PMID: 32084351\n- Autophagy in meningeal macrophages maintains CSF immune surveillance PMID: 33888909\n\n**Prediction:** Autophagy augmentation will fully compensate for 50% reduction in recruited immune cells without increasing infection susceptibility.\n\n**Confidence:** 0.45\n\n---\n\n## Hypothesis 6: CXCR3-β-arrestin Biased Agonism for Pathway-Specific Signaling\n\n**Description:** Designing CXCR3 ligands that selectively activate β-arrestin recruitment (G-protein independent) preserves homeostatic CXCR3 functions in synaptic plasticity and neural stem cell migration while blocking G-protein-mediated inflammatory T-cell recruitment.\n\n**Target:** CXCR3 β-arrestin biased signaling pathway\n\n**Supporting Evidence:**\n- CXCR3 signals through both G-protein and β-arrestin pathways with distinct outcomes PMID: 31537709\n- β-arrestin-2 is required for CXCR3-mediated neurogenesis PMID: 30022169\n- Biased agonists separate therapeutic from adverse effects in chemokine receptors PMID: 32049952\n\n**Prediction:** β-arrestin biased CXCR3 ligands will maintain CNS development and synaptic function while blocking pathological T-cell infiltration by >90%.\n\n**Confidence:** 0.40\n\n---\n\n## Hypothesis 7: Tissue-Resident Memory T-Cell (TRM) Seeding Enhancement via Topical CXCL10 Delivery\n\n**Description:** Intranasal CXCL10 administration during treatment holidays enhances CNS-resident memory T-cell (TRM) seeding, creating a local sentinel population that maintains autonomous immune surveillance independent of peripheral cell recruitment, compensating for CXCL10 blockade effects.\n\n**Target:** CNS TRM population expansion (via CXCL10 gradients)\n\n**Supporting Evidence:**\n- CXCL10 is essential for CD8+ TRM cell establishment in non-lymphoid tissues PMID: 32576520\n- TRM cells provide long-term autonomous immunity independent of circulating T cells PMID: 33106665\n- CNS TRM cells protect against viral reactivation without systemic immune activation PMID: 32840604\n\n**Prediction:** CXCL10-boosted TRM seeding will provide ≥70% protection against HSV-1 reactivation despite ongoing CXCL10 blockade.\n\n**Confidence:** 0.45\n\n---\n\n**Synthesis:** These hypotheses collectively address the safety gap through three mechanistic strategies: (1) smarter receptor engagement (H1, H6), (2) spatial targeting specificity (H2), and (3) temporal/compensatory approaches (H3, H4, H5, H7). The highest-priority translation pathway is **Hypothesis 1** (CXCR3 partial agonism), which offers the most direct mechanistic solution with existing pharmacological precedent.",
  "tokens_used": "1754"
}